https://www.yiliao.com/index.php?action=history&feed=atom&title=LCNEC
LCNEC - 版本历史
2026-04-18T05:51:25Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=LCNEC&diff=315895&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-27T06:35:14Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>大细胞肺癌</strong>（Large Cell Lung Cancer, <strong>[[LCLC]]</strong>）是<strong>[[非小细胞肺癌]]</strong>（NSCLC）中一种未分化的亚型，属于典型的<strong>“排他性诊断”</strong>（Diagnosis of Exclusion）。它缺乏小细胞癌、腺癌或鳞癌的细胞结构和免疫组化特征。LCLC 恶性程度极高，生长迅速，早期转移倾向强，预后通常劣于其他 NSCLC 亚型。临床上最需要警惕的是其特殊亚型——<strong>[[大细胞神经内分泌癌]]</strong>（LCNEC），后者的生物学行为和治疗策略更接近<strong>[[小细胞肺癌]]</strong>。根据 <strong>NCCN Guidelines (v1.2026)</strong>，经典大细胞癌通常参照非鳞 NSCLC 标准方案治疗（免疫+化疗），而 LCNEC 则需根据基因分型制定个性化方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden; float: right; margin-left: 20px; margin-bottom: 20px;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">LCLC</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">Large Cell Lung Cancer (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; width: 60px; height: 60px; border-radius: 50%; background: #e0f2fe; border: 2px solid #bae6fd; line-height: 60px; color: #1e40af; font-weight: bold; font-size: 1.2em;">Null</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 10px; font-weight: 600;">特征：无腺/鳞分化标记</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.82em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">ICD-10 编码</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">C34</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">发病率</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 5-10% (呈下降趋势)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">免疫表型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>Null Type</strong> (TTF-1-/p40-)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">特殊亚型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[LCNEC]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">恶性程度</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">高 (High Grade)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要诱因</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">重度吸烟</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">最新指南</th><br />
<td style="padding: 8px 12px; color: #0f172a;">NCCN v1.2026</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">病理诊断：排除法的艺术</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
根据 2021 WHO 胸部肿瘤分类，大细胞癌的诊断必须建立在手术切除标本之上（穿刺活检通常只能报“NSCLC-NOS”）。其核心特征是缺乏腺癌（TTF-1）和鳞癌（p40）的标志物。<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.88em; text-align: left;"><br />
<tr style="background-color: #eff6ff; color: #1e40af;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 20%; vertical-align: top;">亚型分类</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 40%; vertical-align: top;">免疫组化 (IHC) 特征</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 40%; vertical-align: top;">临床意义与治疗导向</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top; font-weight: 600; color: #0f172a;"><br />
<strong>经典大细胞癌</strong><br><br />
<span style="font-size:0.85em; color:#64748b; font-weight:normal;">(LCLC-NOS)</span><br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top;"><br />
• <strong>Null 表型</strong>：<br><br />
&nbsp;&nbsp;TTF-1 (-), Napsin A (-)<br><br />
&nbsp;&nbsp;p40 (-), p63 (-), CK5/6 (-)<br><br />
&nbsp;&nbsp;神经内分泌标记 (-)<br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top; background-color: #f0fdf4;"><br />
<span style="color: #166534; font-weight: bold;">按非鳞 NSCLC 治疗</span><br><br />
• 必须排除肉瘤样癌。<br><br />
• 基因突变谱（KRAS, STK11）与吸烟相关腺癌相似。<br><br />
• <strong>[[PD-1]]</strong> 免疫治疗通常有效。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top; font-weight: 600; color: #b91c1c;"><br />
<strong>大细胞神经内分泌癌</strong><br><br />
(<strong>[[LCNEC]]</strong>)<br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top;"><br />
• <strong>NE 标记阳性</strong>：<br><br />
&nbsp;&nbsp;CD56 (+), Synaptophysin (+)<br><br />
• 伴有非小细胞形态特征<br><br />
• 高增殖指数 (Ki-67 高)<br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top;"><br />
<span style="color: #b91c1c; font-weight: bold;">预后极差，治疗争议大</span><br><br />
• <strong>RB1 缺失型</strong>：生物学行为类 SCLC，对铂+依托泊苷敏感。<br><br />
• <strong>RB1 野生型</strong>：类 NSCLC，对吉西他滨/紫杉醇敏感。<br />
</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f0fdf4; color: #166534; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #166534; font-weight: bold;">治疗策略 (NCCN 2026)</h2><br />
<div style="background-color: #f0fdf4; border-left: 5px solid #22c55e; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #14532d; font-size: 1.1em;">治疗原则</h3><br />
<p style="margin-bottom: 0; color: #334155; font-size: 0.95em;"><br />
经典 LCLC 的治疗与肺腺癌类似，主要依赖<strong>免疫+化疗</strong>。而 LCNEC 的治疗则处于“灰色地带”，需结合基因检测结果（TP53/RB1 状态）来决定是按 SCLC 还是 NSCLC 方案治疗。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.88em; text-align: left;"><br />
<tr style="background-color: #eff6ff; color: #1e40af;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 15%; vertical-align: top;">分期</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 25%; vertical-align: top;">治疗目标</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 60%; vertical-align: top;">标准治疗路径</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top; font-weight: 600; color: #15803d;"><br />
早期/局晚期<br><span style="font-size:0.85em; font-weight:normal; color:#64748b;">(I - III期)</span><br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top; color: #15803d; font-weight: bold;"><br />
根治 (Curative)<br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top;"><br />
• <strong>首选手术</strong>：肺叶切除 + 淋巴结清扫。<br><br />
• <strong>围手术期治疗</strong>：<br><br />
&nbsp;&nbsp;经典 LCLC：同 [[非小细胞肺癌]]，推荐 <strong>[[围手术期免疫]]</strong> (Chemo-IO)。<br><br />
&nbsp;&nbsp;LCNEC：通常推荐围手术期化疗 (EP方案)，类似 SCLC。<br />
</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top; font-weight: 600; color: #475569;"><br />
晚期<br><span style="font-size:0.85em; font-weight:normal; color:#64748b;">(IV期)</span><br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top; color: #475569; font-weight: bold;"><br />
延长生存<br />
</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; vertical-align: top;"><br />
• <strong>基因检测 (-)</strong>：<br><br />
&nbsp;&nbsp;首选 <strong>[[帕博利珠单抗]]</strong> + 培美曲塞 + 铂类（KEYNOTE-189模式）。<br><br />
• <strong>特殊突变 (+)</strong>：<br><br />
&nbsp;&nbsp;虽然罕见，但若检出 KRAS G12C 或 BRAF V600E，可用相应靶向药。<br><br />
• <strong>LCNEC</strong>：<br><br />
&nbsp;&nbsp;首选依托泊苷 + 铂类 (EP方案) 或 免疫联合化疗。<br />
</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>NCCN Clinical Practice Guidelines in Oncology.</strong> <em>Non-Small Cell Lung Cancer. Version 1.2026.</em><br><br />
<span style="color: #475569;">[包含大细胞癌诊疗规范]：明确了 LCLC 尤其是 LCNEC 的分层治疗原则。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Travis WD, et al. (2015).</strong> <em>The 2015 World Health Organization Classification of Lung Tumors.</em> <strong>[[Journal of Thoracic Oncology]]</strong>.<br><br />
<span style="color: #475569;">[病理金标准]：确立了基于免疫组化（Null 表型）的大细胞癌诊断标准。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Derks JL, et al. (2024).</strong> <em>Clinical outcomes of emerging therapeutic targets in large cell neuroendocrine carcinoma.</em> <strong>[[Journal of Thoracic Oncology]]</strong>.<br><br />
<span style="color: #475569;">[LCNEC 突破]：探讨了基于 RB1/TP53 基因分型的 LCNEC 精准治疗策略。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Rekhtman N, et al. (2016).</strong> <em>Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma.</em> <strong>[[Clinical Cancer Research]]</strong>.<br><br />
<span style="color: #475569;">[基因图谱]：揭示了 LCNEC 在分子层面上分为“类 SCLC 型”和“类 NSCLC 型”的异质性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
LCLC · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心概念</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[非小细胞肺癌]]</strong> • <strong>[[LCNEC]]</strong> • <strong>[[小细胞肺癌]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">治疗手段</td><br />
<td style="padding: 10px 15px; color: #334155;">[[免疫治疗]] • [[依托泊苷]] • [[培美曲塞]] • [[排他性诊断]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020